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Aim: to identify the serum complement 3 (C3) and 
complement 4 (C4) level in febrile neutropenia and non-
febrile neutropenia patients.
Methods: this is a cross-sectional prospective study. 
Samples were collected from patients with febrile neutrope-
nia as sample group and patients with neutropenia but 
without fever as control. Both groups were tested for serum 
complement 3 and complement 4 level, and the data were 
analyzed using student T- test.
Results: from 37 neutropenia patients, 23 were 
classied as febrile neutropenia group and 14 in non-febrile 
neutropenia as control group. Total mean neutrophil count 
was 653.22/ ml serum in sample group and 594.36/ ml serum 
in control group (p = 0.575). Mean C3 level was 95.74 ug/dl 
in sample group and 130.00 ug/dl in control group, showing 
signicant difference with p= 0.031. The mean serum C4 
level was 34.13 ug/ml in sample group and 34.00 ug /dl in 
control group, the difference is not signicant with p = 0.98. 
When sample C3 and C4 data were combined, the total level 
was 125.61 ug/ml, which was signicantly lower than the total 
C3 and C4 in control group 184.07 ug/dl. (p = 0,04)
Conclusion: in febrile neutropenia there is signicant 
decrease of serum C3 level compared to non-febrile 
neutropenia. Serum C4 level in febrile neutropenia group 
is lower than the non-febrile neutropenia group, but the 
difference is not signicant. 
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INTRODUCTION 
Infectious diseases still remain an essential health 
problem, especially in some developing countries 
including Indonesia. Infectious disease is caused by 
growth of microorganisms in the human body, causing 
wounds and tissue damage which lead to inammation. 
The clinical manifestation of systemic inammation 
could be SIRS (systemic inflammatory response 
syndrome) which consists of: tachypneu (respiratory 
rate over >20 breaths per minute with PaCO2 < 32 Torr), 
tachycardia (pulse >100 times/minute), hyperthermia or 
hypothermia (axillary temperature > 380 C or < 35,50C), 
leukocytosis or leukopenia (leukocyte count >10.000 
cells/mm3 or <6000 cells/mm3). The inflammatory 
reaction is related to various body components, such as: 
vascular, neural tissue, body uid and cells, especially 
at the wound site.1,2 
The body uid also contains several body compo-
nents and cells responsible in inammation, including 
macrophage and leukocyte, especially neutrophil/
polymorphonuclear neutrophil (PMN) and complement 
system, especially complement 3 (C3 ) and complement 
4 (C4). 
The PMN neutrophil is able to synthesize and to 
express adhesive receptors, then will attach to and pass 
through the vascular wall (perdiapedesis) to migrate into 
related tissue. This neutrophil activity is a response to 
chemotactic agents produced at the site of inammation: 
the chemotactic agents include IL-8, complement-derived 
factors (C3a, C5a), calcrein, cytokine from TH1 cell and 
chemotactic factors produced by mast cell.3-6, 28,35,37 
There are several nonspecific factors that could 
fortify the antibody effect: phagocyte cell (macrophage 
cell and neutrophil leukocyte) that could destroy antigen/ 
bacteria and complement, where besides directly 
destroying the antigen/bacteria, complement also 
functions as facilitator through opsonization process to 
assist phagocytosis by phagocyte cells.3,4 
15
Vol 40 • Number 1 • January 2008                     Serum Complement 3 (C3) and Complement 4 (C4) Level
Some patients were found to have neutropenia, 
these particular people have decreased phagocytosis 
ability but do not have fever, this is due to 
another factor that also contributes in phagocytosis, 
the opsonization. Opsonization is a process to 
prepare for phagocytosis, where the bacteria 
is covered by antibody and the complement 
system before being phagocytosized. Therefore in 
patients with neutropenia there are complement 
deciencies especially C3 and C4, so the phagocytosis 
ability extremely decreases and the patients become 
really prone to infection, marked by the presence of 
fever/febrile neutropenia.3,6,7,16,22,38
Neutropenia or neutrophil deciency is a condition 
where the absolute neutrophil count (ANC) decreases to 
below 1500 cells/mm3 of blood. During its course some 
neutropenia will also show fever (febrile neutropenia) 
and some others do not experience fever (non febrile 
neutropenia). It has been mentioned previously, in 
some literature, severe neutropenia will cause critical 
illness, where some of the patients will undergo sepsis 
which may lead to septic shock.1,2,30,36 
One must wonder whether there is a difference of 
immune response in febrile and non-febrile neutropenia. 
One of immune response system is complement, which 
then raises the question whether there is a difference of 
complement level in patients with febrile and non-febrile 
neutropenia. The aim of this study is to discover the level 
of C3 and C4 complement in patients with febrile and 
non-febrile neutropenia admitted to Dr. Kariadi Hospital, 
Semarang, and Dr. Moewardi Hospital, Surakarta. 
METHODS
This is a prospective study with cross-sectional 
approach. Stastical analysis was performed using 
student T-test to compare the level of complement in 
patients with febrile and non-febrile neutropenia using 
SPSS for Windows 11.5.8 
Inclusion Criteria
The patients are 18 years-old or older. Patients with 
neutropenia admitted to Dr. Kariadi Hospital, Semarang, 
and Dr. Moewardi Hospital, Surakarta, during February 
1st 2005-June 31st 2005, who had had routine blood 
examination including leucocyte count and differential 
which determined ANC (absolute neutrophil count), 
and suffered from fever of >38oC (result from two 
observations within 1 hour). The patients or family 
representing the patients agreed to be included in 
the study. 
Exclusion Criteria
The patients or family representing the patients were 
not consent to be included in the study. 
Materials and Methods
The material studied are blood specimen from 
neutropenic patients who fulll the inclusion criteria. 
Sample size includes all samples that fulll inclusion 
criteria, based on prevalence of neutropenia in general 
population, 13%-50%, using Lemeshow and Lwanga 
formula (1990).9
Subjects meeting the study’s criteria were questioned 
for anamnesis, underwent physical examination, blood 
examination (hemoglobin level, erythrocyte count, 
leukocyte count, hemogram and thrombocyte count). 
The ANC is calculated afterwards. The group of subjects 
with febrile neutropenia became sample group, while 
subjects with non-febrile neutropenia became control 
group. Then, body sera were drawn from each subject 
of both groups for C3 and C4 examination using 
Immunoturbidimetry assay according to Tina-quant 
(2003).10
Duration of study was done from March 2003 to 
February 2004. 
RESULTS
There were 37 cases of neutropenia being studied 
from March 2003 to February 2004, consisted of 23 
febrile neutropenia as sample group and 14 cases of 
non-febrile-neutropenia as control group.(Table 1) Of 37 
subjects, 19 were male and 18 were female. The 
youngest were 18 years old and the oldest were 75 
years old with mean age of 42.81 years. Mean age for 
sample group was 42.70 years while in control group 
46.86 years, which, statistically, was not signicantly 
different (p=0.43).
T-test Result
a.   Neutrophil count. Of 23 sample group, mean 
neutrophil count was 53.22/mL, while in 14 subjects 
of control group it was 594.36/mL. Both results were 
not signicantly different (p=0.575). (Table 2)
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b.   C3 Level. Mean of C3 level in sample group was 
95.47 µg/dL, while in control group 130.00 µg/dL. 
Mean of C3 level in sample group is signicantly 
higher compared to in control group with p=0.031.
c.   C4 Levels. Mean of C4 level of sample group was 
34.13 ìg/dL, while in control group 34.00 µg/dL. 
Even though C4 level in sample group was higher 
than in control group, it was not significantly 
different  p=0.98.
d.   Total C3 and C4 Level. Even though C3 held a 
central role in complement system, actually 
complement system worked synergistically. Thus, 
we tried to combine the level of C3 and C4. When C3 
and C4 complement levels of the sample group were 
combined the mean result was 125.61 µg/dL, which 
was lower than normal level, 130 µg/dL. It was 
signicantly lower compared to the level of C3 
and C4 in control group, which was 184.07 µg/dL, 
p=0.040.
pathway is affected, the disease manifested will be 
correlated with immune system disorder. Furthermore, 
for protection against tissue damage due to overactive 
complement mediator, complement system is equipped 
with regulation of soluble protein and protein in the 
cell membrane.3,5,31,32
The study found that mean level of C3 in the sample 
group (94.74 µg/mL) was below normal level (105 
µg/mL); while mean level of C3 in control group was 
130.00 µg/mL, which was above that of the sample 
group. The result was signicantly different in statistical 
perspective with p=0.031 (p<0.05).
The mean level of C4 in sample group (n=23 
subjects) was 34.13 µg/dL, which was under normal 
C4 level (25 mg/dL). Meanwhile, mean level of control 
group was 34.00 µg/ml, which was also above normal 
level. Mean level of C4 in sample group was higher than 
control group, however this margin was not statistically 
different (p=0.984).
 Complement in vivo works as an integrated system 
(complement system). When C3 and C4 level of sample 
group was added, the mean level was 125.61 µg/dL. 
This result was lower than C3 and C4 total in normal 
person (130 µg/dL). Mean of total C3 and C4 in control 
group was 184.07 µg/dL, which was higher than mean 
in the sample group with signicant statistical difference 
(p=0.040).14,15
The decrease of C3 in patients with febrile 
neutropenia (sample group) in comparison to non-febrile 
neutropenia group (control) was in accordance with the 
opinion of previous researcher (Chapel H et al [2001]; 
Kirschnk and Mulines [2003]; Atkinson [2003]), that 
C3 had central role in several process of complement 
activation in assisting phagocytosis process.3,12,18
The result of this study is almost similar to Guntur 
(2000), however, in this study, from immunocompro-
mised (IC) patients (14 subjects) and non-immunocom-
promised (NIC) patients (14 subjects), the mean of C3 
level was 1.050 and 1.449, respectively. Statistically, 
there was signicant difference of both group (p=0.016). 
Meanwhile, mean levels of C4 in IC group and NIC 
group were 24.289 and 27.929, respectively, with no 
signicant difference in statistics (p>0.05).17
In other study by Guntur (2002), it was reported 
that out of 27 sepsis cases being studied, 22 cases were 
improving and 5 cases deteriorated into septic shock. 
The study group were sepsis group and septic shock 
group, who underwent examination for several variables: 
IL-10, IFN-γ , TNF-α, IL-Iβ, IgG, C3 and C4. The result 
of mean level of C3 in septic shock group was lower 
than sepsis group with statistical signicant difference 
(p<0.05). However, even though the mean level of C4 
DISCUSSION
Complement system was rst discovered as 
thermolabile substance in serum, involved in perfecting 
antibody in eliminating bacteria or immune complex.
Almost all complement component produced by 
liver is in inactive form, thus, in order to function, 
must be activated—usually by infectious stimuli or 
immunostimulant.3-7,11-15,29,33,34
Kirschfink and Mulines (2003) stated that 
complement is activated through 3 pathways: classical 
pathway, alternative pathway, and Lectin pathway 
(MBL). All three pathways require activation of 
complement 3 (C3) as central/main component, which 
will generate a Cytolitic Membrane Attack (MAC) 
complex derived from C5b-9, or the fourth or terminal 
pathway.4,12,24,29
Defect in complement system will increase 
susceptibility to infection; especially when classical 
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in septic shock group was lower than sepsis group, the 
difference was not statistically signicant.18,19
Our study, along with other previous research, has 
shown that mean level of C3 in sample and control 
group are signicantly different. Such condition showed 
the important role of C3 physiologically in assisting 
phagocytosis component by preparing opsonization 
process toward foreign matters, whether bacteria, 
virus or other matters, to be eliminated in complete 
phagocytosis by macrophage or neutrophil.
Similar to the concept proposed by Atkinson (2003) 
that complement activation for opsonization process 
and MAC (membrane attack complex) formation must 
encompass C3b component, which was synthesized from 
C3.20 Markiewski MM et al (2004) and Suresh M et al 
(2003) reported that C3a and C3b, synthesis of C3, played 
an important role in hepatocyte regeneration due to 
intoxication. It was predicted that C3b/iC3b facilitated 
phagocytocis of necrotic and apoptotic cells by 
macrophages.21,23
As reported by Guntur (2002), patients with sepsis 
underwent increase of C3 level because in sepsis 
there was drastic increase of IL-10, which will acceler-
ate B lymphocyte maturation, causing plasma cell 
differentiation and increasing IgG level. IgG will bind 
immunogenic chemical substances forming a complex 
which will activate and increase C3 level. C3 derives to 
the synthesis of C3a and C3b. C3a will accelerate C5a 
synthesis; both substances are named anaphylatoxin 
compound which will cause vascular dilatation, decrease 
vascular resistance and increase vascular permeability 
causing plasma extravasation.24 (Figure 1)
The importance of C3 role could also be seen in 
the study by Shauna et al (2004), which stated that 
Burkholderia pseudomallei often cause septicemia 
because B. pseudomallei contain polysaccharide 
capsule capable to block CR1 or CR3 receptor and 
decrease C3b level, causing inadequate phagocytosis 
process.25
Prevention of over-activation of C3/C3a was also 
stated by Girardi G et al (2003) and Atkinson C et 
al (2005). Atkinson C et al stated that Intestinal 
ischemia/reperfusion injury (IRI) was the main complica-
tion of abdominal surgery, cardiopulmonal bypass, rup-
ture of abdominal aneurism, and cardiac arrest. Decrease 
in abdominal circulation causes hemorrhagic shock and 
intestinal IRI leading to bacteria translocation and 
sepsis. IRI causes intestinal dysfunction indicated by 
decrease in motility, increase of permeability and 
mucosal wall injury. All condition are partly mediated 
by complement activation and neutrophil inltration. IRI 
can be prevented by activating CR2, which will inhibit 
accumulation of C3d/C3 that leads to accumulation 
of C3a. C3a accumulation will accelerate synthesis 
of C5a, tissue destroyer. Girardi et al recommended 
C5-antibody medication—a peptide of anti-C5aR, 
anti-granulocyte and anti-neutrophil ability which 
can prevent pregnancy failure in APL (antibody anti-
phospholipid) cases.26,27
CONCLUSION
C3 plays a central role in complement activation and 
function in opsonization process in assisting phagocytosis 
by macrophage and/or neutrophil. 
C3 is the first complement component in the 
immune system that can react to external immunogen/
microorganism. Thus, decrease in C3 will increase the 
body’s susceptibility to infection.
For better justication of the study result, more 
samples are required.
In the future, C3 levels can be considered as a 
predictor for prognostic factor of infection, especially 
in sepsis.
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